AU2009231634B2 - Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof - Google Patents

Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof Download PDF

Info

Publication number
AU2009231634B2
AU2009231634B2 AU2009231634A AU2009231634A AU2009231634B2 AU 2009231634 B2 AU2009231634 B2 AU 2009231634B2 AU 2009231634 A AU2009231634 A AU 2009231634A AU 2009231634 A AU2009231634 A AU 2009231634A AU 2009231634 B2 AU2009231634 B2 AU 2009231634B2
Authority
AU
Australia
Prior art keywords
compound
hyaluronan
fha
skin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009231634A
Other languages
English (en)
Other versions
AU2009231634A1 (en
AU2009231634A2 (en
Inventor
Thomas P. Kennedy
Glenn Prestwich
Narayanam Rao
Xiayou Xu
Jianxing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2009231634A1 publication Critical patent/AU2009231634A1/en
Publication of AU2009231634A2 publication Critical patent/AU2009231634A2/en
Application granted granted Critical
Publication of AU2009231634B2 publication Critical patent/AU2009231634B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
AU2009231634A 2008-04-04 2009-04-03 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof Active AU2009231634B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4231008P 2008-04-04 2008-04-04
US61/042,310 2008-04-04
PCT/US2009/039498 WO2009124266A2 (en) 2008-04-04 2009-04-03 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof

Publications (3)

Publication Number Publication Date
AU2009231634A1 AU2009231634A1 (en) 2009-10-08
AU2009231634A2 AU2009231634A2 (en) 2012-04-12
AU2009231634B2 true AU2009231634B2 (en) 2014-05-15

Family

ID=41055226

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009231634A Active AU2009231634B2 (en) 2008-04-04 2009-04-03 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof

Country Status (10)

Country Link
US (5) US7855187B1 (https=)
EP (1) EP2281008B1 (https=)
JP (1) JP5758797B2 (https=)
KR (1) KR101594552B1 (https=)
CN (1) CN102177180A (https=)
AU (1) AU2009231634B2 (https=)
BR (1) BRPI0909849A2 (https=)
CA (1) CA2719666C (https=)
MX (1) MX2010010904A (https=)
WO (1) WO2009124266A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2280720T1 (sl) 2008-03-27 2019-06-28 Purdue Research Foundation Sintetični peptidoglikani,ki vežejo kolagen, priprava in postopki uporabe
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
CA2719666C (en) 2008-04-04 2016-08-16 Glenn Prestwich Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
WO2011094149A1 (en) * 2010-01-26 2011-08-04 University Of Utah Research Foundation Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
CA2790682C (en) * 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
KR20140042795A (ko) * 2011-03-23 2014-04-07 유니버시티 오브 유타 리서치 파운데이션 비뇨기 염증을 치료 또는 예방하는 방법
WO2012129461A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
HRP20170482T1 (hr) 2011-05-24 2017-05-19 Symic Ip, Llc Sintetski peptidoglikani koji vežu hijaluronsku kiselinu, dobivanje, i postupci uporabe
JP5873319B2 (ja) * 2011-12-16 2016-03-01 株式会社コーセー メイラード反応阻害剤
CN104144950B (zh) 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
EP2849773A1 (en) * 2012-05-14 2015-03-25 University of Southern California Methods for limiting development of a skin wound
WO2013172923A1 (en) 2012-05-15 2013-11-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Uses of antagonists of hyaluronan signaling
US9828444B2 (en) * 2012-12-12 2017-11-28 Solvay Specialty Polymers Italy S.P.A. Fluorinated chitosan derivatives
US9200039B2 (en) 2013-03-15 2015-12-01 Symic Ip, Llc Extracellular matrix-binding synthetic peptidoglycans
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
SG11201603081WA (en) * 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
CA2931726C (en) * 2013-11-25 2022-03-15 Deuteria Biomaterials, Llc Deuterium-enriched hyaluronan
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US9637712B2 (en) 2014-01-10 2017-05-02 Lost Spirits Distillery, Llc Method for rapid maturation of distilled spirits using light and heat processes
US9637713B2 (en) 2014-01-10 2017-05-02 Lost Spirits Distillery, Llc Method for rapid maturation of distilled spirits using light and heat processes
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
PL3352766T3 (pl) 2015-09-24 2021-08-02 Matrix Biology Institute Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia
ITUB20155623A1 (it) * 2015-11-16 2017-05-16 Fidia Farm Spa Processo migliorato per la produzione di HA solfatato di elevata purezza
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
WO2019010484A2 (en) 2017-07-07 2019-01-10 Symic Ip, Llc SYNTHETIC BIOCONJUGATES
WO2019079535A1 (en) * 2017-10-18 2019-04-25 Glycomira Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS
CN108586574B (zh) * 2018-04-26 2019-11-12 国家海洋局第三海洋研究所 氨基葡萄糖肽类化合物及其制备方法与应用
WO2019236453A1 (en) 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
JP7492967B2 (ja) 2019-01-30 2024-05-30 ボシュ・アンド・ロム・インコーポレイテッド 架橋ポリマーネットワークおよびその使用
WO2022157307A1 (en) * 2021-01-22 2022-07-28 Dsm Ip Assets B.V. Hyaluronic acid as antimicrobial agent for use on the skin
WO2022157314A1 (en) * 2021-01-22 2022-07-28 Dsm Ip Assets B.V. Hyaluronic acid for use on the skin
CN112972490B (zh) * 2021-03-04 2022-02-18 中国人民解放军军事科学院军事医学研究院 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199687A1 (en) * 2002-04-11 2003-10-23 Manssur Yalpani Biocompatible materials and probes
FR2864090A1 (fr) * 2003-12-19 2005-06-24 Aventis Pharma Sa Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
WO2007006403A2 (en) * 2005-07-07 2007-01-18 Fidia Advanced Biopolymers S.R.L. Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2599172A (en) 1948-11-29 1952-06-03 Searle & Co Sulfuric acid esters of hyaluronic acid and processes for the production thereof
US4240163A (en) * 1979-01-31 1980-12-23 Galin Miles A Medicament coated intraocular lens
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584728B1 (fr) 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
SE453394B (sv) * 1986-07-07 1988-02-01 Pharmacia Ab Forfarande for framstellning av sulfaterade polysackarider genom anvendning av ett reducerande medel for sulfateringsreaktionen
EP0285357A3 (en) 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
DK505588D0 (da) 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
IT1217458B (it) 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
JP2769584B2 (ja) * 1990-06-04 1998-06-25 参天製薬株式会社 局所投与用抗アレルギー剤
IT1247175B (it) 1991-04-19 1994-12-12 Fidia Spa Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico.
UA35578C2 (uk) 1991-08-16 2001-04-16 Майлс Е. Гелін Передньокамерний очний імплантат, спосіб його одержання та спосіб лікування короткозорості
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
DE69621528T2 (de) 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
GB2317182B (en) 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
JPH10195107A (ja) 1997-01-10 1998-07-28 Shiseido Co Ltd オリゴ硫酸化ヒアルロン酸
DE69809892T2 (de) * 1997-04-04 2003-08-28 Fidia Advanced Biopolymers S.R.L., Brindisi N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung
US5981509A (en) 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
IT1293484B1 (it) 1997-06-11 1999-03-01 Fidia Advanced Biopolymers Srl Materiale biologico comprendente una efficiente coltura di cellule e una matrice tridimensionale biocompatibile e biodegradabile
IT1294797B1 (it) * 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
ITPD980037A1 (it) 1998-02-25 1999-08-25 Fidia Advanced Biopolymers Srl Acido ialuronico solfatato e i suoi derivati legati covalentemente a polimeri sintetici pe la preparazione di biomateriali e per il rivesti
DE19813234A1 (de) 1998-03-26 1999-09-30 Knoell Hans Forschung Ev Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren
JPH11279042A (ja) 1998-03-30 1999-10-12 Shiseido Co Ltd 皮膚外用剤
US6984667B2 (en) 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
ITPD980149A1 (it) 1998-06-17 1999-12-17 Fidia Advanced Biopolymers Srl Protesi tridimensionali comprendenti derivati dell'acido ialuronico per riparare o ricostruire i tessuti danneggiati e processo per la
WO2000006608A1 (en) 1998-07-31 2000-02-10 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
IT1306644B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
US6288043B1 (en) 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
JP2001097997A (ja) 1999-10-01 2001-04-10 Shiseido Co Ltd 硫酸化ヒアルロン酸を用いたアフィニティー吸着担体及びその使用
JP4139029B2 (ja) * 1999-12-10 2008-08-27 大阪瓦斯株式会社 電源装置
JP2001163789A (ja) 1999-12-13 2001-06-19 Maruho Co Ltd マトリックスメタロプロテアーゼ阻害用医薬組成物
EP2845596A3 (en) 2000-01-10 2015-07-15 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
IT1317359B1 (it) * 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e
DE10053053A1 (de) 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
ITPD20020064A1 (it) 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
JP2005531647A (ja) 2002-04-11 2005-10-20 カルボマー インク 新規なイメージングプローブ
MXPA05000186A (es) 2002-07-03 2005-08-17 Pericor Science Inc Composiciones de acido hialuronico y metodos de uso.
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
DE10352137A1 (de) 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Verwendung sulfatierter Hyaluronsäure
WO2005056608A1 (en) 2003-12-04 2005-06-23 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
US20050203056A1 (en) * 2003-12-19 2005-09-15 Aventis Pharma S.A. Carboxyl-reduced derivatives of hyaluronic acid, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them
ITPD20040245A1 (it) 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali
DE102005004643B4 (de) 2005-01-28 2010-04-08 Innovent E.V. Technologieentwicklung Antivirale Kombinationen sowie ihre Verwendung
JP2006206849A (ja) 2005-01-31 2006-08-10 Seikagaku Kogyo Co Ltd アルキルエステル化されたグリコサミノグリカンの製造方法
WO2006105313A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions of and methods of using oversulfated glycosaminoglycans
WO2006108022A1 (en) 2005-04-04 2006-10-12 Neoparin, Inc. Process for the induction of intramolecular migration of sulfates, phosphates, and other oxyanions
US7993678B2 (en) 2005-09-26 2011-08-09 Novozymes Biopolymer A/S Hyaluronic acid derivatives
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
CA2625532C (en) 2005-10-12 2013-10-01 Seikagaku Corporation Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan
WO2007059890A1 (en) 2005-11-22 2007-05-31 Centre National De Recherche Scientifique New derivatives of hyaluronic acid, their preparation process and their uses
US20070166266A1 (en) 2006-01-19 2007-07-19 Solazyme, Inc. Methods and compositions for improving the health and appearance of skin
DK1994062T3 (da) 2006-03-02 2009-11-16 Novozymes Biopharma Dk As Aryl/alkyl-vinylsulfonhyaluronsyrederivater
ITPD20060219A1 (it) * 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
CN101511876A (zh) 2006-07-11 2009-08-19 犹他大学研究基金会 用亲电子基团修饰的大分子及其制备和使用方法
KR20090053892A (ko) 2006-07-25 2009-05-28 오스모티카 코프. 점안액
TW200838552A (en) 2007-01-25 2008-10-01 Novozymes Biopolymer As Methyl esters of hyaluronic acid
JP5088864B2 (ja) 2007-03-16 2012-12-05 オリンパス株式会社 生体組織補填材とその製造方法
EP2025687A1 (en) 2007-07-23 2009-02-18 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
US20100249064A1 (en) * 2007-09-07 2010-09-30 University Of Chicago Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan
EP2057983A1 (en) 2007-11-07 2009-05-13 Bruschettini S.r.l. Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations
WO2009111159A2 (en) 2008-03-03 2009-09-11 New York University Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same
CA2719666C (en) 2008-04-04 2016-08-16 Glenn Prestwich Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
CA2750188C (en) 2009-02-02 2016-11-29 Otsuka Chemical Co., Ltd. Low-molecular polysulfated hyaluronic acid derivative and compositions containing same
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
IT1393945B1 (it) 2009-04-21 2012-05-17 Fidia Farmaceutici Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche
IT1397247B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
IT1397246B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
WO2012129461A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199687A1 (en) * 2002-04-11 2003-10-23 Manssur Yalpani Biocompatible materials and probes
FR2864090A1 (fr) * 2003-12-19 2005-06-24 Aventis Pharma Sa Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
WO2007006403A2 (en) * 2005-07-07 2007-01-18 Fidia Advanced Biopolymers S.R.L. Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process

Also Published As

Publication number Publication date
US20100317616A1 (en) 2010-12-16
CN102177180A (zh) 2011-09-07
US20150209385A1 (en) 2015-07-30
CA2719666C (en) 2016-08-16
MX2010010904A (es) 2010-11-04
AU2009231634A1 (en) 2009-10-08
US7855187B1 (en) 2010-12-21
AU2009231634A2 (en) 2012-04-12
US8399430B2 (en) 2013-03-19
CA2719666A1 (en) 2009-10-08
KR20110004422A (ko) 2011-01-13
US20120058161A1 (en) 2012-03-08
US20130190234A1 (en) 2013-07-25
EP2281008B1 (en) 2017-01-04
WO2009124266A2 (en) 2009-10-08
EP2281008A2 (en) 2011-02-09
BRPI0909849A2 (pt) 2015-10-06
US8951990B2 (en) 2015-02-10
WO2009124266A3 (en) 2009-12-17
US9549945B2 (en) 2017-01-24
JP5758797B2 (ja) 2015-08-05
KR101594552B1 (ko) 2016-02-17
US8329673B2 (en) 2012-12-11
JP2011516672A (ja) 2011-05-26
US20110082104A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
AU2009231634B2 (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
CA2838493C (en) Applications of partially and fully sulfated hyaluronan
US10179147B2 (en) Applications of partially and fully sulfated hyaluronan
TWI639434B (zh) 用於局部施用之包含玻尿酸和幾丁聚醣之黏膜黏性組成物
US10226481B2 (en) Pharmaceutical compositions composed of low molecular weight sulfated hyaluronan
RU2576033C2 (ru) Составы на основе гиперсулфатированных дисахаридов
HK1157800A (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
KR20140042795A (ko) 비뇨기 염증을 치료 또는 예방하는 방법

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 NOV 2010

FGA Letters patent sealed or granted (standard patent)